Jami Rubin
Stock Analyst at Goldman Sachs
(1.16)
# 3,640
Out of 4,900 analysts
14
Total ratings
40%
Success rate
-4.56%
Average return
Main Sectors:
Stocks Rated by Jami Rubin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 | $16.42 | +82.70% | 2 | Oct 1, 2018 | |
| PRGO Perrigo Company | Downgrades: Sell | $78 → $74 | $27.41 | +169.97% | 7 | Jul 12, 2018 | |
| JNJ Johnson & Johnson | Upgrades: Neutral | n/a | $156.82 | - | 2 | Jul 12, 2018 | |
| MRK Merck & Co. | Upgrades: Buy | n/a | $83.67 | - | 1 | Apr 23, 2018 | |
| LLY Eli Lilly and Company | Downgrades: Neutral | n/a | $799.34 | - | 1 | Jan 16, 2018 | |
| ABBV AbbVie | Maintains: Buy | $74 → $80 | $191.52 | -58.23% | 1 | Mar 10, 2017 |
Teva Pharmaceutical Industries
Oct 1, 2018
Maintains: Buy
Price Target: $30
Current: $16.42
Upside: +82.70%
Perrigo Company
Jul 12, 2018
Downgrades: Sell
Price Target: $78 → $74
Current: $27.41
Upside: +169.97%
Johnson & Johnson
Jul 12, 2018
Upgrades: Neutral
Price Target: n/a
Current: $156.82
Upside: -
Merck & Co.
Apr 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $83.67
Upside: -
Eli Lilly and Company
Jan 16, 2018
Downgrades: Neutral
Price Target: n/a
Current: $799.34
Upside: -
AbbVie
Mar 10, 2017
Maintains: Buy
Price Target: $74 → $80
Current: $191.52
Upside: -58.23%